Patent SG-11201805451T-A (SG)
Title: Immune effector cell therapies with enhanced efficacy
Inventor: MOTZ GREGORY
IPC: C12N5/0783
Filed: 2016-12-30
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization MD 1111101110101011111 HO 11111 01E3 $1110 1111111 01111111101111011# International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/114497 Al 6 July 2017 (06.07.2017) WI P0 I P CT (51) International Patent Classification: [CN/CN]; c/o CNIBR, No. 4218 Jinke Road, Shanghai C12N 5/0783 (2010.01) C07D 295/00 (2006.01) 201203 (CN). MAO, Qitao [CN/CN]; c/o CNIBR, No. C12N 15/113 (2010.01) 4218 Jinke Road, Shanghai 201203 (CN). (21) International Application Number: (74) Agent: ZHONGZI LAW OFFICE; 7F, New Era Build- PCT/CN2016/113612 ing, 26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN). (22) International Filing Date: 30 December 2016 (30.12.2016) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/CN2015/099882 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 30 December 2015 (30.12.2015) CN MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 4056 Basel (CH). THE TRUSTEES OF THE UNIVER- RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, SITY OF PENNSYLVANIA [US/US]; Suite 200, 3160 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Chestnut Street, Philadelphia, Pennsylvania 19104-3242 ZA, ZM, ZW. (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors; and kind of regional protection available): ARIPO (BW, GH, Applicants (for US only): MOTZ, Gregory [US/US]; 83 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, — (71) Greene Street, Quincy, Massachusetts 02170 (US). MAV- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, RAKIAS, Konstantinos John [US/US]; c/o Novartis In- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, stitutes for Biomedical Research, Inc., 250 Massachusetts DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Avenue, Cambridge, Massachusetts 02139 (US). LIU, Jin-LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, biao [CN/CN]; China Novartis Institutes for Biomedical SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Research, No. 8 Building, Lane 898, Halei Road, Zhangji- ang Hi-Tech Park, Pudong New Area, Shanghai 201203 Published: — = (CN). LIU, Lei [CN/CN]; Building 2, No. 3728 Jinke = — Road, Shanghai 201203 (CN). ZHENG, Qiangang with international search report (Art. 21(3)) = [CN/CN]; Room 11-302, Nanjiao Garden, Lane 118, — with sequence listing part of description (Rule 5.2(a)) Zhoukang Road, Shanghai 201318 (CN). XUN, Guoliang = = = = = = = 1-1 IN C:7 7r 7r 11 11 IN 11 © (54) Title: IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY ei 0 (57) : Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease as- sociated with expression of a tumor antigen.